Athena Neurosciences Inc., which last week announced a transgenic mouse model for Alzheimer's disease, stands to reap a substantial payback from a very modest and quietly executed acquisition of Exemplar Corp.'s work in transgenic disease models.
By overexpressing a mutated human gene for the amyloid precursor protein (APP), the mouse achieves what biotechnology has sought for years - an animal mimic of the human condition, at least at the level of brain histology. Previous models have failed to show the extensive pathology found in this mouse strain, according to ATHN.